218 related articles for article (PubMed ID: 36741416)
1. Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP.
Vijver SV; Danklmaier S; Pipperger L; Gronauer R; Floriani G; Hackl H; Das K; Wollmann G
Front Immunol; 2022; 13():1100730. PubMed ID: 36741416
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
3. Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants.
Pipperger L; Riepler L; Kimpel J; Siller A; Stoitzner P; Bánki Z; von Laer D
Oncoimmunology; 2021; 10(1):1959140. PubMed ID: 34484872
[TBL] [Abstract][Full Text] [Related]
4. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
Nelson A; Gebremeskel S; Lichty BD; Johnston B
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
[TBL] [Abstract][Full Text] [Related]
5. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D
Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639
[TBL] [Abstract][Full Text] [Related]
6. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
7. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
8. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
[TBL] [Abstract][Full Text] [Related]
9. Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum.
Pipperger L; Koske I; Wild N; Müllauer B; Krenn D; Stoiber H; Wollmann G; Kimpel J; von Laer D; Bánki Z
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243134
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
[TBL] [Abstract][Full Text] [Related]
11. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.
Willmon CL; Saloura V; Fridlender ZG; Wongthida P; Diaz RM; Thompson J; Kottke T; Federspiel M; Barber G; Albelda SM; Vile RG
Cancer Res; 2009 Oct; 69(19):7713-20. PubMed ID: 19773437
[TBL] [Abstract][Full Text] [Related]
12. Vesicular Stomatitis Virus (VSV) G Glycoprotein Can Be Modified to Create a Her2/Neu-Targeted VSV That Eliminates Large Implanted Mammary Tumors.
Gao Y; Bergman I
J Virol; 2023 Jun; 97(6):e0037223. PubMed ID: 37199666
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
14. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
[TBL] [Abstract][Full Text] [Related]
15. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
16. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
[TBL] [Abstract][Full Text] [Related]
17. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
[TBL] [Abstract][Full Text] [Related]
18. Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.
Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Pulido J; Pavelko K; Pease L; Melcher A; Vile R
Cancer Res; 2010 Jun; 70(11):4539-49. PubMed ID: 20484025
[TBL] [Abstract][Full Text] [Related]
19. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
20. A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.
Das K; Belnoue E; Rossi M; Hofer T; Danklmaier S; Nolden T; Schreiber LM; Angerer K; Kimpel J; Hoegler S; Spiesschaert B; Kenner L; von Laer D; Elbers K; Derouazi M; Wollmann G
Nat Commun; 2021 Aug; 12(1):5195. PubMed ID: 34465781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
